Clinical Significance of Soluble Programmed Cell Death-1 and Soluble Programmed Cell Death-Ligand 1 in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy

PLoS ONE - United States
doi 10.1371/journal.pone.0212978
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Role of Soluble Programmed Death-1 (sPD-1) and sPD-ligand 1 in Patients With Cystic Echinococcosis

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2015English

Predictive Role of Computed Tomography Texture Analysis in Patients With Metastatic Urothelial Cancer Treated With Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors

European urology oncology
OncologyRadiologyUrologyNuclear MedicineImagingSurgery
2019English

2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer

Open Forum Infectious Diseases
OncologyNeurology
2018English

Elevated Serum Soluble Programmed Cell Death Ligand 1 Concentration as a Potential Marker for Poor Prognosis in Small Cell Lung Cancer Patients With Chemotherapy

Respiratory Research
PulmonaryRespiratory Medicine
2018English

Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy

JAMA Dermatology
DermatologyMedicine
2016English

Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals With Sepsis: A Systematic Review and Meta-Analysis

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2018English

Expression of Programmed Cell Death-Ligand 1 and Its Correlation With Clinical Outcomes in Gliomas

Oncotarget
Oncology
2016English

Clinical Significance of Serum Soluble Death Receptor 5 Concentration in Locally Advanced Non‑small Cell Lung Cancer Patients

Oncology Letters
Cancer ResearchOncology
2014English

Diverse Cutaneous Adverse Eruptions Caused by Anti-Programmed Cell Death-1 (PD-1) and Anti-Programmed Cell Death Ligand-1 (PD-L1) Immunotherapies: Clinical Features and Management

Therapeutic Advances in Medical Oncology
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy